Physician profile
Paul Lindner
NPI 1730166521
$3,832.68
in general payments reported to CMS, 2019-2025
35 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $212 · 2021: $689 · 2022: $1,018 · 2023: $652 · 2024: $393 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,314.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $788.54 | 2019-2023 | |
| Hologic Sales and Service, LLC | $523.77 | 2019-2025 | Acessa Provu System, Novasure |
| Daiichi Sankyo INC. | $421.02 | 2019-2025 | Injectafer |
| Astellas Pharma US INC | $249.77 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $206.36 | 2019-2025 | Evenity, Prolia |
| Minerva Surgical, INC | $188.29 | 2019-2023 | |
| Pfizer INC. | $165.81 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $147.10 | 2023-2025 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $135.93 | 2021-2022 | |
| Organon LLC | $133.04 | 2021-2024 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $114.92 | 2019-2025 | |
| Momentis Surgical INC. | $107.00 | 2022 | |
| Exeltis, USA INC. | $95.50 | 2021-2025 | Slynd |
| Merck Sharp & Dohme LLC | $73.44 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $67.05 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $48.90 | 2024 | Interstim |
| Therapeuticsmd, INC. | $43.65 | 2021 | |
| Scynexis, INC. | $34.92 | 2022 | |
| Amag Pharmaceuticals, INC. | $26.56 | 2019 | |
| Ascend Therapeutics US, LLC | $24.49 | 2021 | |
| Aspira Women'S Health INC | $23.95 | 2024 | Ova1 |
| Coopersurgical, INC. | $22.62 | 2019-2020 | |
| Novo Nordisk INC | $21.26 | 2025 | Wegovy |
| Lupin INC. | $19.06 | 2019 | |
| Mimedx Group, INC. | $19.03 | 2025 | |
| Convatec INC. | $16.84 | 2021 | |
| Teleflex LLC | $16.12 | 2020 | |
| Virtus Pharmaceuticals LLC | $15.36 | 2021 | |
| Covidien LP | $14.67 | 2019 | |
| Avion Pharmaceuticals | $13.50 | 2022 | |
| Meditrina | $12.81 | 2024 | |
| Allergan, INC. | $12.66 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.39 | 2019 | |
| Glaxosmithkline, LLC. | $11.72 | 2019 | |
| Alydia Health | $4.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lindner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.